Premium
Pharmacokinetics of 23‐Epi‐26‐Deoxyactein in Women After Oral Administration of a Standardized Extract of Black Cohosh
Author(s) -
Breemen R B,
Liang W,
Banuvar S,
Shulman L P,
Pang Y,
Tao Y,
Nikolic D,
Krock K M,
Fabricant D S,
Chen SN,
Hedayat S,
Bolton J L,
Pauli G F,
Piersen C E,
Krause E C,
Geller S E,
Farnsworth N R
Publication year - 2010
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2009.251
Subject(s) - black cohosh , pharmacokinetics , pharmacology , dose , urine , medicine , clinical pharmacology , oral administration , hormone , chemistry , menopause
Dietary supplements containing black cohosh are alternatives to conventional hormone replacement therapy in menopause. This study investigates the maximum tolerated dose of a 75% ethanol extract of black cohosh and determines the pharmacokinetics of one of its most abundant triterpene glycosides, 23‐epi‐26‐deoxyactein. Single doses of black cohosh extract containing 1.4, 2.8, or 5.6 mg of 23‐epi‐26‐deoxyactein were administered to 15 healthy, menopausal women. Serial blood samples and 24‐h urine samples were obtained; blood chemistry, hormonal levels, and 23‐epi‐26‐deoxyactein levels were determined. No acute toxicity or estrogenic hormone effects were observed. Pharmacokinetic analyses of 23‐epi‐26‐deoxyactein in sera indicated that the maximum concentration and area under the curve increased proportionately with dosage, and that the half‐life was ~2 h for all dosages. Less than 0.01% of the 23‐epi‐26‐deoxyactein was recovered in urine 24 h after administration. No phase I or phase II metabolites were observed either in clinical specimens or in vitro . Clinical Pharmacology & Therapeutics (2010) 87 2, 219–225. doi: 10.1038/clpt.2009.251